Multimodality Therapy in the Treatment of Lung Cancer

 

 Buy Article Permissions and Reprints

Lung cancer is the leading cause of cancer death in the world, causing more than one million deaths each year. The incidence and mortality rates are highest in the United States and Europe and continue to increase in developing nations. Non-small cell lung cancer (NSCLC) accounts for 80 to 85% of all new cases of lung cancer. The majority of patients with NSCLC present with advanced disease at the time of diagnosis. Although the prognosis of advanced NSCLC is very poor, current chemotherapy combinations have been shown to improve 1-year survival and quality of life for these patients. Approximately one third of patients with NSCLC are diagnosed with locally advanced disease. Although cure rates are modest and variable in locally advanced NSCLC, multimodality therapy (chemotherapy in combination with surgery or radiotherapy) has resulted in statistically significant improvement in 5-year survival when compared with surgery or radiotherapy alone. Patients with early-stage NSCLC have the best long-term survival rates following surgical resection; however, systemic recurrences remain a problem in the majority of these patients. The rationale for treating patients with early-stage NSCLC with combined-modality therapy (chemotherapy and surgery) is compelling, and several randomized trials are currently in progress. Although progress has been slow, when we consider the recent advances in smoking prevention, smoking cessation, staging classification, imaging and diagnostic techniques, screening and therapeutic modalities, and multidisciplinary care, as well as in the understanding of the molecular pathogenesis of lung cancer, the future, in my opinion, is very promising.

REFERENCES

• 1 Jemal A, Murray T, Samuels A et al.. Cancer statistics, 2003.  CA Cancer J Clin. 2003;  53 5-26
  CrossrefPubMedGoogle Scholar
• 2 Travis W D, Travis L B, Devesa S S. Lung cancer.  Cancer. 1995;  75 191-202
  CrossrefPubMedGoogle Scholar
• 3 Humphrey E W, Smart C R, Winchester D P et al.. National survey of the pattern of care for carcinoma of the lung.  J Thorac Cardiovasc Surg. 1990;  100 837-843
  PubMedGoogle Scholar
• 4 World Health Organization .World health report, 1997: executive summary. Geneva; World Health Organization 1997: 1-13
  Google Scholar
• 5 Parkin D M, Pisani P, Ferlay J. Global cancer statistics.  CA Cancer J Clin. 1999;  49 33-64
  CrossrefPubMedGoogle Scholar
• 6 Wingo P A, Tong T, Bolden S. Cancer statistics, 1995.  CA Cancer J Clin. 1995;  45 8-30
  PubMedGoogle Scholar
• 7 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.  BMJ. 1995;  311 899-909
  Google Scholar
• 8 Marino P, Pampallona S, Preatoni A et al.. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature.  Chest. 1994;  106 861-865
  CrossrefPubMedGoogle Scholar
• 9 Crinò L, Scagliotti G, Marangolo M et al.. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): a phase II study [abstract 1066].  Proc Am Soc Clin Oncol. 1995;  14 352a
  PubMedGoogle Scholar
• 10 Langer C J, Leighton J C, Comis R L et al.. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.  J Clin Oncol. 1995;  13 1860-1870
  PubMedGoogle Scholar
• 11 Wozniak A J, Crowley J J, Balcerzak S P et al.. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.  J Clin Oncol. 1998;  16 2459-2465
  PubMedGoogle Scholar
• 12 Schiller J H, Harrington D, Belani C P et al.. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.  N Engl J Med. 2002;  346 92-98
  CrossrefPubMedGoogle Scholar
• 13 Cullen M H, Billingham L J, Woodroffe C M et al.. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.  J Clin Oncol. 1999;  17 3188-3194
  PubMedGoogle Scholar
• 14 Ellis P A, Smith I E, Hardy J R et al.. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.  Br J Cancer. 1995;  71 366-370
  PubMedGoogle Scholar
• 15 Mountain C F, Dressler C M. Revisions in the international staging system for lung cancer.  Chest. 1997;  111 1718-1723
  CrossrefPubMedGoogle Scholar
• 16 Pearson F, DeLarue N C, Ilves R et al.. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung.  J Thorac Cardiovasc Surg. 1982;  83 1-11
  PubMedGoogle Scholar
• 17 Martini N, Flehinger B J. The role of surgery in N2 lung cancer.  Surg Clin North Am. 1987;  67 1037-1049
  PubMedGoogle Scholar
• 18 Depierre A, Milleron B, Moro-Sibilot D et al.. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.  J Clin Oncol. 2002;  20 247-253
  CrossrefPubMedGoogle Scholar
• 19 Keller S M, Adak S, Wagner H et al.. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.  N Engl J Med. 2000;  343 1217-1222
  CrossrefPubMedGoogle Scholar
• 20 Andre F, Grunenwald D, Pignon J P et al.. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.  J Clin Oncol. 2000;  18 2981-2989
  CrossrefPubMedGoogle Scholar
• 21 Wagner Jr H, Lad T, Piantadosi S et al.. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.  Chest. 1994;  106(suppl 6) S348-S354
  PubMedGoogle Scholar
• 22 Roth J A, Fossella F, Komaki R et al.. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  J Natl Cancer Inst. 1994;  86 673-680
  CrossrefPubMedGoogle Scholar
• 23 Rosell R, Gomez-Codina J, Camps C et al.. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med. 1994;  330 153-158
  CrossrefPubMedGoogle Scholar
• 24 Elias A D, Herndon J, Kumar P et al.. A phase III comparison of “best local-regional therapy” with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results [abstract 1611].  Proc Am Soc Clin Oncol. 1997;  16 448a
  PubMedGoogle Scholar
• 25 Roth J A, Atkinson E N, Fossella F et al.. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  Lung Cancer. 1998;  21 1-6
  CrossrefPubMedGoogle Scholar
• 26 Rosell R, Gomez-Codina J, Camps C et al.. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.  Lung Cancer. 1999;  26 7-14
  CrossrefPubMedGoogle Scholar
• 27 Yoneda S, Hibino S, Gotoh I et al.. A comparative trial on induction chemoradiotherapy followed by surgery (CRS) or immediate surgery (IS) for stage III non-small cell lung cancer (NSCLC) [abstract 1128].  Proc Am Soc Clin Oncol. 1995;  14 367a
  PubMedGoogle Scholar
• 28 Perez C A, Pajak T F, Rubin P et al.. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group.  Cancer. 1987;  59 1874-1881
  CrossrefPubMedGoogle Scholar
• 29 Dillman R O, Herndon J, Seagren S L et al.. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.  J Natl Cancer Inst. 1996;  88 1210-1215
  CrossrefPubMedGoogle Scholar
• 30 Sause W, Kolesar P, Taylor IV S et al.. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.  Chest. 2000;  117 358-364
  CrossrefPubMedGoogle Scholar
• 31 Pritchard R S, Anthony S P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta- analysis.  Ann Intern Med. 1996;  125 723-729
  PubMedGoogle Scholar
• 32 Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis.  Cancer. 1995;  76 593-601
  CrossrefPubMedGoogle Scholar
• 33 Furuse K, Fukuoka M, Kawahara M et al.. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.  J Clin Oncol. 1999;  17 2692-2699
  CrossrefPubMedGoogle Scholar
• 34 Curran W, Scott C, Langer C et al.. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract 303].  Lung Cancer. 2000;  29(suppl 1)
  PubMedGoogle Scholar
• 35 Jeremic B, Shibamoto Y, Acimovic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.  J Clin Oncol. 1996;  14 1065-1070
  CrossrefPubMedGoogle Scholar
• 36 Schaake-Konig C, van den Bogaert W, Dalesio O et al.. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.  N Engl J Med. 1992;  326 524-530
  PubMedGoogle Scholar
• 37 Bulzebruck H, Bopp R, Drings P et al.. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification.  Cancer. 1992;  70 1102-1110
  PubMedGoogle Scholar
• 38 Mountain C F. Revisions in the international system for staging lung cancer.  Chest. 1990;  97 1045-1051
  PubMedGoogle Scholar
• 39 Inoue H, Sato M, Fujimura S et al.. Prognostic assessment of 1310 patients with non-small cell lung cancer who underwent complete resection from 1980 to 1993.  J Thorac Cardiovasc Surg. 1998;  116 407-411
  CrossrefPubMedGoogle Scholar
• 40 Hensing T A, Detterbeck F, Socinski M A. The role of induction therapy in the management of resectable non-small cell lung cancer.  Cancer Control. 2000;  7 45-55
  PubMedGoogle Scholar
• 41 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials.  BMJ. 1995;  311 899-909
  Google Scholar
• 42 Tonato M. Final report of the Adjuvant Lung Project Italy (ALPI): an Italian/EORTC-LCG randomised trial of adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC) [abstract 1157].  Proc Am Soc Clin Oncol. 2002;  21 290a
  PubMedGoogle Scholar
• 43 The International Adjuvant Lung Cancer Trial collaborative Group . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.  N Engl J Med. 2004;  350 351-360
  CrossrefPubMedGoogle Scholar
• 44 Pisters K M, Ginsberg R J, Giroux D J et al.. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach.  J Thorac Cardiovasc Surg. 2000;  119 429-439
  CrossrefPubMedGoogle Scholar
• 45 From the Centers for Disease Control and Prevention: declines in lung cancer rates-California, 1988-1997.  JAMA. 2000;  284 3121-3122
  CrossrefPubMedGoogle Scholar
• 46 Peto R, Darby S, Deo H et al.. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies.  BMJ. 2000;  321 323-329
  CrossrefPubMedGoogle Scholar
• 47 Ferrara N. Molecular and biologic properties of vascular endothelial growth factor.  J Mol Med. 1999;  77 527-543
  CrossrefPubMedGoogle Scholar
• 48 Franklin W A, Veve R, Hirsch F R et al.. Epidermal growth factor receptor family in lung cancer and premalignancy.  Semin Oncol. 2002;  29(suppl 4) S3-S14
  PubMedGoogle Scholar
• 49 Herbst R S, Langer C J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.  Semin Oncol. 2002;  29(suppl 4) S27-S36
  PubMedGoogle Scholar
• 50 Ciardiello F, Caputo R, Bianco R et al.. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.  Clin Cancer Res. 2000;  6 2053-2063
  PubMedGoogle Scholar
• 51 Perez-Soler R, Chachoua A, Huberman M et al.. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235].  Proc Am Soc Clin Oncol. 2001;  20 310a
  PubMedGoogle Scholar

M. Patricia RiveraM.D. F.C.C.P. 

University of North Carolina at Chapel Hill, Division of Pulmonary and Critical Care Medicine, CB# 7020

130 Mason Farm Rd., 4133 Bioinformatics Bldg.

Chapel Hill, NC 27599-7020

Email: mprivera@med.unc.edu